2-dose HPV vaccine schedule provides sufficient protection for over 2 years: Study
Israel: After the last dose of a 2-dose 9vHPV vaccine regimen in boys and girls, antibody response persists through 2 to 2.5 years, finds a recent study in the journal Pediatrics.
The findings suggests that antibody response generated by administering 2 doses administered 6 to 12 months apart may be sufficient to induce high-level protective efficacy at least for 2 years after the second dose.
A recent international, randomized, open-label trial found human papillomavirus (HPV) antibody responses to the 9-valent human papillomavirus (9vHPV) vaccine among girls and boys (aged 9–14 years) receiving 2-dose regimens (months 0, 6 or 0, 12) to be non inferior to a 3-dose regimen (months 0, 2, 6) in young women (aged 16–26 years) 4 weeks after last vaccination. Jacob Bornstein, Galilee Medical Center and Azrieli Faculty of Medicine, Bar-Ilan University, Nahariya, Israel, and colleagues assessed response durability through month 36.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.